Comparing Water Vapour Thermal Therapy (Rezūm) and TURP
Launched by CHINESE UNIVERSITY OF HONG KONG · Feb 28, 2023
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is comparing two treatments for men with urinary problems related to an enlarged prostate, specifically looking at a new method called water vapour thermal therapy (Rezūm) versus a traditional procedure known as transurethral resection of the prostate (TURP). The goal is to see if the new treatment is just as effective as the standard one. The trial is currently recruiting men between the ages of 50 and 80 who have been experiencing urinary retention and are currently using a catheter. To be eligible, men must have a prostate size between 30 to 80 milliliters and not have had any prior prostate surgeries or a history of prostate cancer.
Participants in this trial can expect to be randomly assigned to either the Rezūm group or the TURP group. Throughout the study, their urinary symptoms will be monitored to determine how well each treatment works. It's important to note that some men may not qualify for this trial if they have certain medical conditions or if they cannot safely undergo either treatment. This trial is an opportunity to contribute to research that may help improve treatment options for men dealing with similar urinary issues in the future.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Men 50-80 years
- • Refractory urinary retention related to benign prostatic hyperplasia (BPH)
- • On urethral Foley's catheter before treatment
- • Prostate size 30-80ml on ultrasound
- Exclusion Criteria:
- • Prior prostate operation
- • Past or current history of prostate cancer
- • Strong suspicion of prostate cancer (e.g. Elevated PSA before urinary retention or abnormal prostate on DRE without workup for prostate cancer)
- • Known Urethral stricture / Bladder stone / Hypocontractile bladder
- • Known neurological diseases which may affect bladder function (e.g. Parkinsonism, stroke)
- • Contraindicated to undergo TURP or REZUM (e.g. not fit for GA/SA, active urinary tract infection, fail to be placed in lithotomy position, uncorrectable coagulopathy, antiplatelet or anticoagulant which cannot be stopped)
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Peter Ka-Fung CHIU, FRCS, PhD
Principal Investigator
Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials